|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:activities
|
inhibits DNA synthesis
|
|
gptkbp:appointed_by
|
intravenous infusion
|
|
gptkbp:approves
|
gptkb:1996
gptkb:FDA
|
|
gptkbp:availability
|
prescription only
|
|
gptkbp:brand
|
gemcitabine hydrochloride
|
|
gptkbp:can_be_used_with
|
gptkb:paclitaxel
gptkb:cisplatin
gptkb:carboplatin
|
|
gptkbp:class
|
gptkb:fragrance
|
|
gptkbp:clinical_trial
|
combination therapy
Phase III
monotherapy
|
|
gptkbp:contraindication
|
pregnancy
breastfeeding
severe renal impairment
hypersensitivity to gemcitabine
|
|
gptkbp:dosage_form
|
lyophilized powder
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Gemzar
|
|
gptkbp:ingredients
|
gptkb:gemcitabine
C9 H11 N3 O4
|
|
gptkbp:interacts_with
|
radiation therapy
other chemotherapy agents
NSAI Ds
|
|
gptkbp:is_atype_of
|
L01 B C03
|
|
gptkbp:is_used_for
|
treating breast cancer
treating non-small cell lung cancer
treating pancreatic cancer
|
|
gptkbp:manufacturer
|
gptkb:Eli_Lilly_and_Company
|
|
gptkbp:marketed_as
|
gptkb:legislation
gptkb:United_States
gptkb:Native_American_tribe
|
|
gptkbp:pharmacokinetics
|
excreted in urine
metabolized in the liver
cytotoxic effects on cancer cells
|
|
gptkbp:population
|
adults
children (with caution)
|
|
gptkbp:previous_name
|
gptkb:gemcitabine
|
|
gptkbp:price
|
varies by region
|
|
gptkbp:requires
|
gptkb:stock_market_index
|
|
gptkbp:research
|
clinical trials
off-label uses
|
|
gptkbp:scholarships
|
stay hydrated
monitor blood counts
avoid live vaccines
report signs of infection
|
|
gptkbp:side_effect
|
fatigue
nausea
vomiting
low blood cell counts
|
|
gptkbp:storage
|
room temperature
|
|
gptkbp:type_of
|
95058-81-4
|
|
gptkbp:bfsParent
|
gptkb:gemcitabine
|
|
gptkbp:bfsLayer
|
5
|